Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591138324> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2591138324 endingPage "362" @default.
- W2591138324 startingPage "362" @default.
- W2591138324 abstract "362 Background: Mutation and/or methylation of the von Hippel-Lindau gene leading to overexpression of hypoxia-inducible factor-1 alpha (HIF1α) has been implicated as a driving event in the pathogenesis of ccRCC. Downstream effectors of HIF1α such as VEGF have become key targets of novel therapies for MccRCC (eg, sunitinib (S)). Carbonic anhydrase-IX (CAIX) transcription is also regulated by HIF1α and is overexpressed in ~95% of ccRCC. Linkage of cG250 (Girentuximab), a chimeric antibody to CAIX, to radioactive iodine ( 124 I), has resulted in a radiotracer specific for ccRCC; 124 I-cG250 ( 124 I-Girentuximab) PET/CT demonstrated a sensitivity of 86% and a specificity of 87% for detecting primary ccRCC (Uzzo AUA 2010). Since responses to targeted therapies likely occur on a molecular level before they are detectable with standard imaging, we hypothesize that 124 I-cG250 PET/CT could allow earlier recognition of response or progression to S than CT in pts with MccRCC. Methods: This is a pilot study of 124 I-cG250 PET/CT in 25 pts with MccRCC planned to begin treatment (Tx) with S. 124 I-cG250 PET/CT will be assessed for its ability to predict Tx response during (days 25–28) and at completion (days 39-42) of the first cycle of therapy, in comparison to standard CT imaging at routine intervals. PET/CT and CT will each be interpreted by 1 nuclear medicine physician, who will be blinded to the results of the comparator imaging modality, but aware of the clinical history of the pts. Eligibility include age ≥18, ECOG PS < 2, histologically confirmed MccRCC, Tx planned with S, and radiographic evidence of unidimensionally measurable disease with at least one lesion ≥2 cm in diameter on 16-slice multi-detector CT. Key exclusion criteria include uncontrolled/unstable hyperthyroidism or Grave’s Disease, unstable cardiac disease and uncontrolled seizure disorder or history of CVA or TIA within the past 12 months. Results: NA. Conclusions: This is the first clinical trial to prospectively evaluate the use of a histologically specific imaging modality to measure early changes in ccRCC CAIX protein expression as a predictor of response to biologically targeted Tx. Enrollment will commence in November 2011." @default.
- W2591138324 created "2017-03-03" @default.
- W2591138324 creator A5010076893 @default.
- W2591138324 creator A5015396908 @default.
- W2591138324 creator A5018531384 @default.
- W2591138324 creator A5053093635 @default.
- W2591138324 creator A5059063118 @default.
- W2591138324 date "2012-02-10" @default.
- W2591138324 modified "2023-10-17" @default.
- W2591138324 title "124I-cG250 PET scan for early detection of response to sunitinib in patients (Pts) with metastatic clear cell renal cell carcinoma (MccRCC)." @default.
- W2591138324 doi "https://doi.org/10.1200/jco.2012.30.5_suppl.362" @default.
- W2591138324 hasPublicationYear "2012" @default.
- W2591138324 type Work @default.
- W2591138324 sameAs 2591138324 @default.
- W2591138324 citedByCount "1" @default.
- W2591138324 countsByYear W25911383242020 @default.
- W2591138324 crossrefType "journal-article" @default.
- W2591138324 hasAuthorship W2591138324A5010076893 @default.
- W2591138324 hasAuthorship W2591138324A5015396908 @default.
- W2591138324 hasAuthorship W2591138324A5018531384 @default.
- W2591138324 hasAuthorship W2591138324A5053093635 @default.
- W2591138324 hasAuthorship W2591138324A5059063118 @default.
- W2591138324 hasConcept C142724271 @default.
- W2591138324 hasConcept C2777472916 @default.
- W2591138324 hasConcept C2778560582 @default.
- W2591138324 hasConcept C2779490328 @default.
- W2591138324 hasConcept C2781278892 @default.
- W2591138324 hasConcept C2989005 @default.
- W2591138324 hasConcept C502942594 @default.
- W2591138324 hasConcept C71924100 @default.
- W2591138324 hasConceptScore W2591138324C142724271 @default.
- W2591138324 hasConceptScore W2591138324C2777472916 @default.
- W2591138324 hasConceptScore W2591138324C2778560582 @default.
- W2591138324 hasConceptScore W2591138324C2779490328 @default.
- W2591138324 hasConceptScore W2591138324C2781278892 @default.
- W2591138324 hasConceptScore W2591138324C2989005 @default.
- W2591138324 hasConceptScore W2591138324C502942594 @default.
- W2591138324 hasConceptScore W2591138324C71924100 @default.
- W2591138324 hasIssue "5_suppl" @default.
- W2591138324 hasLocation W25911383241 @default.
- W2591138324 hasOpenAccess W2591138324 @default.
- W2591138324 hasPrimaryLocation W25911383241 @default.
- W2591138324 hasRelatedWork W2011760975 @default.
- W2591138324 hasRelatedWork W2018023354 @default.
- W2591138324 hasRelatedWork W2149281553 @default.
- W2591138324 hasRelatedWork W2760912249 @default.
- W2591138324 hasRelatedWork W2761568558 @default.
- W2591138324 hasRelatedWork W2891780841 @default.
- W2591138324 hasRelatedWork W2913790807 @default.
- W2591138324 hasRelatedWork W3040274980 @default.
- W2591138324 hasRelatedWork W4361918245 @default.
- W2591138324 hasRelatedWork W4366742470 @default.
- W2591138324 hasVolume "30" @default.
- W2591138324 isParatext "false" @default.
- W2591138324 isRetracted "false" @default.
- W2591138324 magId "2591138324" @default.
- W2591138324 workType "article" @default.